TY  - GEN
AU  - Mazzucato, Mariana,
AU  - Dosi, Giovanni
TI  - Knowledge accumulation and industry evolution: the case of Pharma-Biotech 
SN  - 0521858224 (hbk.)
PY  - 2006///
CY  - Cambridge, UK, New York
PB  - Cambridge University Press
KW  - Drug Industry
KW  - Biomedical Research
KW  - Biomedical Technology
KW  - Technology, Pharmaceutical
KW  - Economics, Pharmaceutical
N1  - Includes bibliographical references and index; 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; Giovanni Dosi and Mariana Mazzucato --; Frank R. Lichtenberg --; Paul Nightingale and Surya Mahdi --; Myriam Mariani --; Louis Galambos --; Elena Cefis, Matteo Ciccarelli and Luigi Orsenigo --; Giulio Bottazzi, Fabio Pammolli and Angelo Secchi --; Christian Garavaglia, Franco Malerba and Luigi Orsenigo --; Boyan Jovanovic --; John P. Walsh, Ashish Arora and Wesley M. Cohen --; Fabienne Orsi, Christine Sevilla and Benjamin Coriat --; Pierre Regibeau and Katharine Rockett --; Joyce Tait, Joanna Chataway, Catherine Lyall and David Wield --; Luigi Orsenigo, Giovanni Dosi and Mariana Mazzucato; Introduction; Pharmaceutical innovation as a process of creative destruction; The evolution of pharmaceutical innovation; Firm and regional determinants in innovation models : evidence from biotechnology and traditional chemicals; Innovation and industry evolution : a comment; Heterogeneity and firm growth in the pharmaceutical industry; Growth and diversification patterns of the worldwide pharmaceutical industry; Entry, market structure, and innovation in a "history-friendly" model of the evolution of the pharmaceutical industry; The growth of pharmaceutical firms : a comment; The effects of research tool patents and licensing on biomedical innovation; Upstream patents and public health : the case of genetic testing for breast cancer; Competition, regulation, and intellectual property management in genetically modified foods : evidence from survey data; Governance, policy, and industry strategies : pharmaceuticals and agro-biotechnology; The dynamics of knowledge accumulation, regulation, and appropriability in the pharma-biotech sector : policy issues
ER  -